InvestorsHub Logo
Followers 38
Posts 3344
Boards Moderated 0
Alias Born 01/13/2017

Re: None

Saturday, 01/14/2017 10:24:54 PM

Saturday, January 14, 2017 10:24:54 PM

Post# of 698657
Arcelis Platform from ARGOS

From their website:

"Using material from both disease and blood samples collected from each patient, our Arcelis®-based immunotherapies arm the patient’s dendritic cells to trigger a targeted patient-specific immune response."

They are in a phase three trial nearing completion in April, and it seems like they have the same technology as NWBO. Are you guys aware of this company, obviously they have a different trial design and are going for renal carcinoma.

Tell me your thoughts
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News